Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease

  • Gallego-Durán, Rocío
  • Cerro-Salido, Pablo
  • Gómez-González, Emilio
  • Pareja, María Jesús
  • Ampuero, Javier
  • Rico, María Carmen
  • Aznar, Rafael
  • Vilar-Gómez, Eduardo
  • Bugianesi, Elisabetta
  • Crespo García, Javier
  • González-Sánchez, Francisco José
  • Aparcero, Reyes
  • Moreno-Santos, Inmaculada
  • Soto, Susana
  • Arias-Loste, María Teresa
  • Abad, Javier
  • Ranchal, Isidora
  • Andrade, Raúl J.
  • Calleja, José Luis
  • Pastrana, Miguel
  • Lo lacono, Oreste
  • Romero-Gómez, Manuel
There is a need, in NAFLD management, to develop non-invasive methods to detect steatohepatitis (NASH) and to predict advanced fibrosis stages. We evaluated a tool based on optical analysis of liver magnetic resonance images (MRI) as biomarkers for NASH and fibrosis detection by investigating patients with biopsy-proven NAFLD who underwent magnetic resonance (MR) protocols using 1.5T General Electric (GE) or Philips devices. Two imaging biomarkers (NASHMRI and FibroMRI) were developed, standardised and validated using area under the receiver operating characteristic curve (AUROC) analysis. The results indicated NASHMRI diagnostic accuracy for steatohepatitis detection was 0.83 (95% CI: 0.73–0.93) and FibroMRI diagnostic accuracy for significant fibrosis determination was 0.85 (95% CI: 0.77–0.94). These findings were independent of the MR system used. We conclude that optical analysis of MRI has high potential to define non-invasive imaging biomarkers for the detection of steatohepatitis (NASHMRI) and the prediction of significant fibrosis (FibroMRI) in NAFLD patients., The research leading to these results has received funding from the European Community’s Seventh Framework Programme (FP7/2007–2013) under grant agreement #HEALTH-F2-2009-241762 for the project Fatty Liver Inhibition of Progression (FLIP) and from Consejería de Salud de la Junta de Andalucía under grant agreement #PI-0488-2012/2012. Imaging biomarkers (NASHMRI and FibroMRI) are protected by a European patent #EP15382118., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease

  • Hardy, Timothy
  • Wonders, Kristy
  • Younes, Ramy
  • Aithal, Guruprasad P.
  • Aller, Rocío
  • Allison, Michael
  • Bedossa, Pierre
  • Betsou, Fay
  • Boursier, Jerome
  • Brosnan, M. Julia
  • Burt, Alastair
  • Cobbold, Jeremy
  • Cortez-Pinto, Helena
  • Day, Chris P.
  • Dufour, Jean-François
  • Ekstedt, Mattias
  • Francque, Sven
  • Harrison, Stephen A.
  • Miele, Luca
  • Nasr, Patrik
  • Papatheodoridis, George
  • Petta, Salvatore
  • Tiniakos, Dina
  • Torstenson, Richard
  • Valenti, Luca
  • Holleboom, Adriaan G.
  • Yki-Järvinen, Hannele
  • Geier, Andreas
  • Romero-Gómez, Manuel
  • Ratziu, Vlad
  • Bugianesi, Elisabetta
  • Schattenberg, Jörn M.
  • Anstee, Quentin M.
© 2020 The Author(s)., Non-Alcoholic Fatty Liver Disease (NAFLD), a progressive liver disease that is closely associated with obesity, type 2 diabetes, hypertension and dyslipidaemia, represents an increasing global public health challenge. There is significant variability in the disease course: the majority exhibit only fat accumulation in the liver but a significant minority develop a necroinflammatory form of the disease (non-alcoholic steatohepatitis, NASH) that may progress to cirrhosis and hepatocellular carcinoma. At present our understanding of pathogenesis, disease natural history and long-term outcomes remain incomplete. There is a need for large, well characterised patient cohorts that may be used to address these knowledge gaps and to support the development of better biomarkers and novel therapies. The European NAFLD Registry is an international, prospectively recruited observational cohort study that aims to establish a large, highly-phenotyped patient cohort and linked bioresource. Here we describe the infrastructure, data management and monitoring plans, and the standard operating procedures implemented to ensure the timely and systematic collection of high-quality data and samples. Already recruiting subjects at secondary/tertiary care centres across Europe, the Registry is supporting the European Union IMI2-funded LITMUS ‘Liver Investigation: Testing Marker Utility in Steatohepatitis’ consortium, which is a major international effort to robustly validate biomarkers that diagnose, risk stratify and/or monitor NAFLD progression and liver fibrosis stage. The European NAFLD Registry has the demonstrable capacity to support research and biomarker development at scale and pace., The European NAFLD Registry is supported by the LITMUS (Liver Investigation: Testing Biomarker Utility in Steatohepatitis) consortium funded by the European Union Innovative Medicines Initiative 2 (IMI2) Joint Undertaking under grant agreement 777377, which receives support from the Horizon 2020 Framework Program of European Union and EFPIA. It has also received support from the EPoS (Elucidating Pathways of Steatohepatitis) consortium funded by the Horizon 2020 Framework Program of the European Union under Grant Agreement 634413, the FLIP consortium funded by the Framework Program 7 of the European Union under grant agreement 241762, and an EASL Registry Grant from the European Association for the Study of the Liver.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Impaired function of solute carrier family 19 leads to low folate levels and lipid droplet accumulation in hepatocytes

  • Cano, Ainara
  • Vazquez-Chantada, Mercedes
  • Conde-Vancells, Javier
  • Gonzalez-Lahera, Aintzane
  • Mosen-Ansorena, David
  • Blanco, Francisco J.
  • Cleḿent, Karine
  • Aron-Wisnewsky, Judith
  • Tran, Albert
  • Gual, Philippe
  • García-Monzón, Carmelo
  • Caballería, Joan
  • Castro, Azucena
  • Martínez-Chantar, María Luz
  • Mato, José M.
  • Zhu, Huiping
  • Finnell, Richard H.
  • Aransay, Ana M.
18 p.-5 fig.-2 tab., Low serum folate levels are inversely related to metabolic associated fatty liver disease (MAFLD). The role of the folate transporter gene (SLC19A1) was assessed to clarify its involvement in lipid accumulation during the onset of MAFLD in humans and in liver cells by genomic, transcriptomic, and metabolomic techniques. Genotypes of 3 SNPs in a case-control cohort were initially correlated to clinical and serum MAFLD markers. Subsequently, the expression of 84 key genes in response to the loss of SLC19A1 was evaluated with the aid of an RT2 profiler-array. After shRNA-silencing of SLC19A1 in THLE2 cells, folate and lipid levels were measured by ELISA and staining techniques, respectively. In addition, up to 482 amino acids and lipid metabolites were semi-quantified in SLC19A1-knockdown (KD) cells through ultra-high-performance liquid chromatography coupled with mass spectrometry. SNPs, rs1051266 and rs3788200, were significantly associated with the development of fatty liver for the single-marker allelic test. The minor alleles of these SNPs were associated with a 0.6/−1.67-fold decreased risk of developing MAFLD. When SLC19A1 was KD in THLE2 cells, intracellular folate content was four times lower than in wild-type cells. The lack of functional SLC19A1 provoked significant changes in the regulation of genes associated with lipid droplet accumulation within the cell and the onset of NAFLD. Metabolomic analyses showed a highly altered profile, where most of the species that accumulated in SLC19A1-KD-cells belong to the chemical groups of triacylglycerols, diacylglycerols, polyunsaturated fatty acids, and long chain, highly unsaturated cholesterol esters. In conclusion, the lack of SLC19A1 gene expression in hepatocytes affects the regulation of key genes for normal liver function, reduces intracellular folate levels, and impairs lipid metabolism, which entails lipid droplet accumulation in hepatocytes., This research was supported in part by CYTED 2005–2007 (FIT010000-2005-0013 to AC and AMA); La Caixa Foundation 2007–2009 (ID425 to MLM-CH and AMA); the «Programme Hospitalier de Reserche Clinique» Assistance Publique-Hôpitaux de Paris (AOR 02076); The Commission of the European Communities (Collaborative Project “Hepatic and adipose tissue and functions in the metabolic syndrome” HEPADIP, contract LSHM-CT-2005-018734); the European Union Seventh Framework Program (FP7/2007–2013, under grant agreement n° Health-F2-2009-241762, for the project FLIP and Horizon 2020 Framework Program (EPoS, grant #634413); Gobierno Vasco-Departamento de Salud 2013111114 (to MLM-C), MINECO: SAF2014-54658-R (to MLM-C), Instituto de Salud Carlos III: PIE/00031 (to MLM-C) and EITB Maratoia BIO15/CA/014 (to MLM-C); Basque Foundation for Health Innovation and Research and BBVA Foundation (to JMM, RHF). CTQ2017-83810-R and PID2020-113225GB-I00 from MINECO to FJB; and The Instituto de Salud Carlos III, Spain grants 13/01299 and 17/00535 co-funded with European FEDER funds (to CG-M). This work was also funded by the French Government (National Research Agency, ANR, #ANR-15-CE14-0016-0), INSERM (France) and Association Française pour l’Etude du Foie (AFEF). CIBERehd_ISCIII_MINECO is funded by the Instituto de Salud Carlos III. CIC bioGUNE support was provided from The Department of Industry, Tourism and Trade of the Government of the Autonomous Community of the Basque Country (Etortek, Emaitek and Elkartek Research Programs 2005–2021), the Innovation Technology Department of the Bizkaia County and MINECO for the Severo Ochoa Excellence Accreditation (SEV-2016-0644)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field

  • Gallego-Durán, Rocío
  • Romero-Gómez, Manuel
Non-alcoholic fatty liver disease (NAFLD) is an emerging health concern in both developed and non-developed world, encompassing from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis and liver cancer. Incidence and prevalence of this disease are increasing due to the socioeconomic transition and change to harmful diet. Currently, gold standard method in NAFLD diagnosis is liver biopsy, despite complications and lack of accuracy due to sampling error. Further, pathogenesis of NAFLD is not fully understood, but is well-known that obesity, diabetes and metabolic derangements played a major role in disease development and progression. Besides, gut microbioma and host genetic and epigenetic background could explain considerable interindividual variability. Knowledge that epigenetics, heritable events not caused by changes in DNA sequence, contribute to development of diseases has been a revolution in the last few years. Recently, evidences are accumulating revealing the important role of epigenetics in NAFLD pathogenesis and in NASH genesis. Histone modifications, changes in DNA methylation and aberrant profiles or microRNAs could boost development of NAFLD and transition into clinical relevant status. PNPLA3 genotype GG has been associated with a more progressive disease and epigenetics could modulate this effect. The impact of epigenetic on NAFLD progression could deserve further applications on therapeutic targets together with future non-invasive methods useful for the diagnosis and staging of NAFLD. Gallego-Durán R, Romero-Gómez M. Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field. World J Hepatol 2015; 7(24): 2497-2502 [PMID: 26523202 DOI: 10.4254/wjh.v7.i24.2497], Supported by European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement, No. HEALTH-F2-2009-241762 for the project FLIP; and Consejería de Salud de la Junta de Andalucía, No. PI-0488/2012, Peer reviewed